Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center in Washington, DC.

Details of the presentation are as follows:

Poster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults
Poster Session: Novel Agents
Poster Number: 3
Date: Thursday October 22, 2026
Time: 12:15 PM - 1:30 PM ET
Location: Poster Hall B-C
Presenter: Christopher E. Harris, M.D.

The poster will be available to view on the conference platform during the conference and on the Company’s website here. Further information about IDWeek™ 2026 can be found here.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261013575271/en/

Media and Investors Contact
Jennifer Viera
617-744-3848
[email protected]

Source: Enanta Pharmaceuticals, Inc.

You May Also Be Interested In

• McLane Company Names Chris Smith as Executive Vice President and Chief Operating Officer
• LinkedIn is Growing Impatient with AI-Generated Content
• PRIVACY ALERT: AWKO Law LLP Investigates Central Ohio Primary Care Physicians for Data Breach of 1.4 Million Patient Records